BiondVax to Present at BIO CEO & Investor Conference
BiondVax Pharmaceuticals (Nasdaq: BVXV) has announced that CEO Amir Reichman will present at the BIO CEO & Investor Conference from February 15, 2022. His presentation highlights a new collaboration aimed at developing innovative therapeutic NanoAbs. Participants can access the presentation on-demand through the conference portal or BiondVax's website. The company is also set to hold virtual meetings with investors during the conference.
BiondVax, established to combat infectious diseases, has conducted several clinical trials and aims to expand its portfolio of therapeutic options.
- None.
- None.
JERUSALEM, Feb. 15, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced that CEO Amir Reichman is presenting at the BIO CEO & Investor Conference being held this week.
Mr. Reichman's presentation focuses on BiondVax's new collaboration for development of innovative therapeutic NanoAbs, and is available on-demand to conference participants via the conference portal and on BiondVax's website at https://www.biondvax.com/events/event-bio-ceo-22.
BiondVax's management will be meeting with investors in a virtual 1-1 setting at this conference. If you wish to set up a meeting with management, please do so via the conference portal or speak directly with investor relations at BiondVax.
About BiondVax
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses. Since its inception, the company has executed eight clinical trials including a seven country, 12,400 participant Phase 3 trial of its vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms, beginning with an innovative nanosized antibody (NanoAb) pipeline. For more information, please visit www.biondvax.com.
Contact Details
Company: Joshua E. Phillipson | +972 8 930 2529 | j.phillipson@biondvax.com
Investor Relations: Kenny Green | +1 212 378 8040 | kgreen@edisongroup.com
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements regarding management's participation in investor conferences. These forward-looking statements reflect management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. Risks and uncertainties include, but are not limited to, the risk that BiondVax will not execute an additional agreement with the Max Planck Society and the University Medical Center Göttingen or that it will be delayed; the risk that the therapeutic and commercial potential of NanoAbs will not be met; the risk of a delay in the preclinical and clinical data for NanoAbs, if any; the risk that BiondVax and EIB will not reach agreement with respect to the restructuring of the loan from European Investment Bank; the risk that BiondVax may not be able to secure additional capital on attractive terms, if at all; the risk that the European Investment Bank may accelerate the loans under its finance contract with BiondVax; risks relating to the COVID-19 (coronavirus) pandemic; BiondVax's ability to acquire rights to additional product opportunities; BiondVax's ability to enter into collaborations on terms acceptable to BiondVax or at all; timing of receipt of regulatory approval of BiondVax's manufacturing facility in Jerusalem, if at all or when required; the risk that the manufacturing facility will not be able to be used for a wide variety of applications and other vaccine and treatment technologies, and the risk that drug development involves a lengthy and expensive process with uncertain outcomes. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's prospectus supplement filed with the Securities and Exchange Commission on December 28, 2021. BiondVax undertakes no obligation to revise or update any forward-looking statement for any reason.
View original content:https://www.prnewswire.com/news-releases/biondvax-to-present-at-bio-ceo--investor-conference-301482594.html
SOURCE BiondVax Pharmaceuticals Ltd.
FAQ
What is the purpose of BiondVax's presentation at the BIO CEO & Investor Conference?
When is BiondVax presenting at the BIO CEO & Investor Conference?
How can I access BiondVax's presentation from the BIO CEO & Investor Conference?
What does BiondVax Pharmaceuticals focus on?
What is the stock symbol for BiondVax Pharmaceuticals?
Who can I contact for investor relations at BiondVax?
